• Adageis closed a $2 million seed round at the end of Q4 2024 to support operational expansion, with the funding to enhance backend operations for next-generation software upgrades.
• Upgraded Electronic Health Record EHR”) connectivity will facilitate integration with over 90 EHR systems, while increased sales force investment will help accelerate growth and market adoption.
• Adageis’ AI-powered platform is designed to streamline healthcare operations, optimize provider revenue, and improve patient care outcomes.

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, has secured $2 million in seed financing to enhance its operations and expand its market reach. The funding, which closed at the end of Q4 2024, supports upgrades to the company’s backend infrastructure, allowing for next-generation improvements, expanded Electronic Health Record (“EHR”) system connectivity, and increased sales efforts to promote rapid growth.

With a unique offering in the healthcare space, the company’s ProActive Care Platform uses artificial intelligence to help healthcare providers shift from traditional fee-for-service models to value-based care. This transition enables organizations to reduce costs, improve patient care, and increase reimbursements by meeting key performance metrics.

A significant portion of the seed funding will be used to expand Adageis’ ability to connect with over 90 EHR systems. Seamless integration with widely used platforms like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, will allow providers to implement Adageis’ technology without disrupting their workflows. The company’s flexible API enables smooth implementation and minimizes training time for healthcare professionals.

Adageis has rebranded its platform as a fintech AI solution, emphasizing its ability to simplify the complexities of insurance contracts. By doing so, providers can optimize revenue streams while ensuring high-quality patient care. The company’s technology helps healthcare organizations maximize reimbursements by aligning with value-based care metrics.

The company’s core offerings include:

• Value-Based Care Engine: A comprehensive platform designed to help healthcare organizations transition to value-based care, improving revenue while maintaining high standards of patient care.
• Patented Risk Engine (“PRE”): AI-driven analytics identify high-risk patients and care gaps, helping providers intervene earlier and reduce costs.
• Proactive Efficiency: The system continuously monitors patient health, enabling timely interventions beyond traditional office visits.
• Flexible Integration: Adageis’ technology is compatible with leading EHR systems, ensuring smooth implementation across various healthcare settings.

By leveraging AI, Adageis helps providers navigate complex insurance agreements, optimize patient care, and enhance operational efficiency. The expansion of its sales force will support the rapid adoption of its advanced technology in healthcare markets.

As value-based care continues to gain traction, Adageis’ AI-driven platform offers healthcare organizations a strategic tool to improve patient outcomes and financial performance. With its recent funding, the company is positioned to scale its impact in the evolving healthcare technology landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• One industry expert projects that the price of palladium could double within the next decade.
• The projected increase in palladium prices bodes well for PLG.
• To further strengthen its strategic position, PLG has been exploring opportunities to enhance its processing capabilities.

The palladium market may be poised for a transformation over the next decade, with one industry analyst forecasting a price increase. The anticipated higher price would present a promising opportunity for companies deeply invested in palladium, such as Platinum Group Metals (NYSE American: PLG) (TSX: PTM). As an emerging player in the palladium sector, Platinum Group Metals stands to benefit from favorable market dynamics, potentially enhancing its strategic positioning.

In a recent analysis, Gaius King, a seasoned industry expert, projected that the price of palladium could double within the next 10 years (https://ibn.fm/VrkbT). King attributes this optimistic forecast to several critical factors influencing both supply and demand dynamics. He emphasizes the persistent supply constraints, noting that “palladium supply is inelastic due to the metal being a byproduct of nickel and platinum mining.” This inelasticity implies that even as demand rises, increasing the supply of palladium remains challenging, thereby exerting upward pressure on prices.

On the demand side, King highlights the robust consumption of palladium in the automotive industry, particularly in the manufacturing of catalytic converters for gasoline-powered vehicles. He points out that “stringent emission regulations worldwide are compelling automakers to use more palladium to meet environmental standards.” This regulatory landscape necessitates the incorporation of higher quantities of palladium in catalytic converters to effectively reduce harmful emissions, thereby bolstering demand.

Furthermore, King discusses the limited potential for substitution as a factor sustaining palladium’s demand. While platinum can technically replace palladium in catalytic converters, he notes that “the substitution is not straightforward due to technical challenges and the current price disparity between the two metals.” This complexity in substitution ensures that palladium will remain the preferred choice for manufacturers, maintaining its demand trajectory.

King also addresses the geopolitical risks associated with palladium production, particularly considering that a significant portion of the global supply originates from Russia. He observes that “geopolitical tensions and operational challenges in these regions can disrupt supply chains,” which could further constrain supply and contribute to price volatility. These geopolitical factors underscore the vulnerability of the palladium supply chain, potentially leading to supply shocks that drive prices higher.

An increase in palladium prices would bode well for Platinum Group Metals, which has been actively advancing its strategic initiatives to capitalize on the favorable market conditions (https://ibn.fm/iAttO). Central to PLG’s operations is the Waterberg Project, located on the Northern Limb of South Africa’s Bushveld Complex. This project is envisioned as a large-scale, fully mechanized, shallow, decline-access platinum, palladium, rhodium and gold mine. Notably, the Waterberg Project is projected to be one of the largest and lowest-cost underground platinum group metal (“PGM”) mines globally, positioning PLG advantageously in the market.

In September 2024, PLG announced positive results from an Independent Definitive Feasibility Study Update (“2024 DFS”) for the Waterberg Project (https://ibn.fm/2ANg9). The study confirmed the project’s robust economic and technical viability, reinforcing its potential to become a significant source of four important elements (“4E”) – platinum, palladium, rhodium and gold. The 2024 DFS highlighted increased mineral resources, with measured and indicated resources rising by 9.5% to 33.76 million 4E ounces, and inferred resources increasing by 6.6% to 8.52 million 4E ounces. These findings underscore the project’s capacity to meet the growing demand for palladium in coming years.

To further strengthen its strategic position, PLG has been exploring opportunities to enhance its processing capabilities. In December 2023, the company entered into a Cooperation Agreement with Ajlan & Bros. Mining and Metals Co. to study the establishment of a standalone PGM smelter and base metals refinery in Saudi Arabia. This initiative aims to provide an alternative processing route for the Waterberg Project’s output, potentially enhancing the company’s operational flexibility and market reach. The proposed facility would process PGM concentrate from the Waterberg Project, offering a strategic solution to potential bottlenecks in the existing smelting infrastructure.  Exporting PGM concentrate from South Africa to Saudi Arabia would require an approval from the government of South Africa.

In summary, the projected increase in palladium prices over the next decade presents a significant opportunity for companies such as Platinum Group Metals. With its strategic assets, proactive initiatives and robust financial planning, PLG is well-equipped to benefit from the favorable market dynamics, potentially delivering enhanced value to its stakeholders.

For more information, visit www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

• A strategic rebranding has positioned Newton Golf as a forward-thinking entity committed to enhancing golfers’ performance through meticulously engineered products.
• Central to Newton Golf’s product lineup are the Newton Gravity Putters and Newton Motion Shafts.
• The company is committed to developing tools that not only enhance performance but also make the game more enjoyable.

In the ever-evolving landscape of golf equipment, Newton Golf (NASDAQ: SPGC) has emerged as a beacon of innovation and quality. Formerly operating under the name Sacks Parente Golf, the company underwent a strategic rebranding to align more closely with its mission of integrating advanced physics principles into golf-equipment design. This transformation has positioned Newton Golf as a forward-thinking entity committed to enhancing golfers’ performance through meticulously engineered products.

The rebranding initiative was officially announced late last year, marking a significant milestone in the company’s evolution (https://ibn.fm/Y1m4p). By consolidating its putter and shaft divisions under the Newton Golf umbrella, the company signaled a unified approach to product development and brand identity. This restructuring was not merely a change in name but a reflection of Newton Golf’s dedication to creating equipment that leverages the laws of physics to benefit golfers of all skill levels.

Central to Newton Golf’s product lineup are the Newton Gravity Putters and Newton Motion Shafts (https://ibn.fm/9gDMT). The gravity putters are renowned for their ultra-low balance point (“ULBP”) technology, a feature that promotes a smoother, more controlled putting stroke. This innovation has garnered attention on professional tours, with several PGA Tour champions integrating these putters into their games. The motion shafts are designed to optimize energy transfer and enhance swing consistency, embodying the company’s commitment to precision engineering.

A cornerstone of Newton Golf’s philosophy is its dedication to domestic manufacturing. All products are proudly made in the United States, with putters manufactured in Camarillo, California, and shafts handcrafted in St. Joseph, Missouri. This commitment ensures stringent quality control and supports local economies, reinforcing the company’s ethos of integrity and excellence.

The company’s vision extends beyond product innovation, encompassing a broader mission to make golf equipment that works smarter for all golfers. By focusing on the principles of physics, Newton Golf aims to develop tools that not only enhance performance but also make the game more enjoyable. This approach reflects a modern yet timeless blend of design and functionality, appealing to both traditionalists and contemporary golfers.

In addition to product development, Newton Golf places a strong emphasis on customer engagement and education. Through its website and various media outlets, the company provides insights into equipment technology, helping golfers make informed decisions about their gear. This educational approach fosters a community of informed consumers who appreciate the nuances of golf equipment and its impact on performance.

Newton Golf’s rebranding and strategic initiatives have not gone unnoticed in the golf industry. Several reputable golf publications have featured the company’s products, giving accolades for their innovative designs and performance benefits. These endorsements serve as a testament to Newton Golf’s commitment to excellence and its role as a leader in golf-equipment innovation.

Looking ahead, Newton Golf is poised to continue its trajectory of growth and innovation. With plans to expand its product offerings and further integrate advanced technologies into its designs, the company is set to solidify its position as a pioneer in the golf-equipment industry. Golfers can anticipate new developments that align with Newton Golf’s mission to make the game more accessible, enjoyable, and rewarding.

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SPGC are available in the company’s newsroom at http://ibn.fm/SPGC

• Calidi’s RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery.
• Calidi’s groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body.

Antitumor virotherapy employs viruses that selectively infect and destroy cancer cells while sparing normal tissues. However, a significant challenge in the administration of these viruses is their rapid neutralization by the immune system, limiting their therapeutic efficacy.

To address this challenge, Calidi designed an innovative vaccinia virus strain enveloped with a human cell membrane (extracellular enveloped virus or EEV), providing protection in the bloodstream while targeting distant tumors (https://ibn.fm/c5fWc). Once inside the tumor, virotherapies are designed to selectively replicate and destroy tumor cells. This process activates an immune response and helps train the immune system to recognize and target future cancer cells. Additionally, the platform can target distant tumors and then act as a viral vector to deliver specific gene therapies to tumor sites.

“Calidi’s groundbreaking systemic enveloped virotherapy holds immense promise in revolutionizing the treatment landscape for cancer patients with lung cancer and metastatic advanced solid tumors,” said Allan Camaisa, Calidi Biotherapeutics CEO and board chair. “By providing protection to the virus during administration, our antitumor virotherapy is able to reach and attack the tumor sites and then activate the immune system. This is the first antitumor virotherapy with systemic administration that shows the potential for real efficacy in the clinic.”

Calidi’s innovative approach builds upon years of experience in using stem cells to protect antitumor viruses from neutralization by the patient’s immune system.

In addition to the RTNova platform, Calidi is advancing other clinical programs, including CLD-101 (NeuroNova) and CLD-201 (SuperNova), which are in various stages of development. These programs utilize stem cell–based platforms to deliver antitumor viruses, aiming to treat multiple oncology indications, such as high-grade gliomas and solid tumors. The company’s commitment to pioneering the future of cancer treatment is exemplified by its collaboration with City of Hope, where the fourth and final cohort of patients are being dosed in a phase 1 clinical trial evaluating neural stem cells carrying a tumor-killing adenovirus to treat recurrent high-grade glioma patients. Calidi also recently announced that Northwestern University commenced recruitment for a Phase 1b/2 trial using Calidi’s NeuroNova drug candidate in a multidosing strategy to treat newly diagnosed high-grade glioma.

Calidi Biotherapeutics’ dedication to harnessing the power of antitumor virotherapy positions the company as a leader in the field of cancer immunotherapy. By developing its systemic delivery mechanisms and leveraging the unique properties of enveloped viruses, Calidi is developing treatments that not only target tumors directly but also stimulate the body’s immune system to fight cancer more effectively. As its development programs progress, Calidi continues to make significant strides toward transforming the standard of care for patients with advanced and metastatic cancers.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• The Q1 Virtual Investor Summit will focus on microcap companies that are undervalued, and aim to create connections between leading investors and microcap companies
• Clene’s presentation will be given by CEO Rob Etherington and CFO Morgan Brown
• Clene’s participation in the event comes as the company is moving closer to submitting a New Drug Application to the FDA to secure potential accelerated approval for CNM-Au8^® for ALS
• The company recently partnered with German-based APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8 efficacy in ALS patients.

Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”), will attend the Q1 Virtual Investor Summit event on March 11 to showcase its latest achievements and outline the next steps for lead drug candidate CNM-Au8 (https://ibn.fm/YHqIv).

The company’s presentation will be given by CEO Rob Etherington and CFO Morgan Brown. The presentation starts at 1 p.m. ET. Anyone interested in participating can register at https://ibn.fm/7tHle.

The Q1 Investor Summit will consist of company presentations between 9 a.m. and 4 p.m. ET, along with one-on-one meetings between 8 a.m. and 4 p.m. An exclusive event for investors who specialize in small and microcap stocks, the Summit is a unique opportunity for investors to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what their peers are doing in this market. This quarter’s event focuses on microcap companies that are undervalued.

Clene’s participation in the event comes as the company is moving closer to submitting an NDA (New Drug Application) to the Food and Drug Administration (“FDA”) in the second half of 2025 to secure potential accelerated approval for CNM-Au8 for ALS.

CNM-Au8 is an oral suspension of gold nanocrystals designed to improve cellular energy production and utilization, which is critical for maintaining neuronal health. The drug candidate has been shown to improve central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. By targeting mitochondrial dysfunction, CNM-Au8 can provide neuroprotection and promote remyelination.

The drug candidate has a robust safety profile and has provided evidence of survival benefit from two independent, randomized, double-blind, placebo-controlled clinical trials so far. In these two Phase 2 clinical trials, RESCUE-ALS and the HEALEY ALS Platform Trial, Regimen C, participants who were administered CNM-Au8 saw significant improvement in survival rates, delayed time to clinical worsening, and improvements on the combined assessment of function and survival compared to placebo. These results are supported by declines in the key plasma biomarker, NfL.

The company recently signed an agreement with APST Research GmbH (“APST”) to further analyze NfL data. The data will support analyses recommended by the FDA on the effects of CNM-Au8 in an additional cohort of ALS patients. Clene will use APST’s extensive dataset to compare NfL levels in NIH-sponsored Expanded Access Protocol (“EAP”) participants treated with CNM-Au8 against matched historical ALS controls. The goal is to determine if CNM-Au8 treatment reduces NfL decline, and to demonstrate that the rate of NfL change is associated with survival in the NIH-sponsored EAP ALS population, which would further strengthen Clene’s case for regulatory approval.

There is currently no cure available for ALS, and treatments can only help slow down the disease progression, manage the symptoms, and prevent unnecessary complications. CNM-Au8 can help increase and improve survival rates in ALS patients by enabling the body’s main systems, primarily breathing, to continue. An accelerated approval pathway for CNM-Au8 would offer hope and help obtain the best outcome for people living with ALS, the company believes. According to CDC statistics, approximately 5,000 Americans are diagnosed with ALS each year, and about 30,000 people are currently living with the disease in the U.S. alone (https://ibn.fm/A0t4F).

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

The 6th KOL & MSL Expertise Summit, held on February 26-27, 2025, in Philadelphia, convened professionals from the pharmaceutical and biotechnology sectors to delve into the evolving dynamics between Key Opinion Leaders (“KOLs”) and Medical Science Liaisons (“MSLs”). The summit offered a platform for in-depth discussions on enhancing collaboration, refining insight programs, and aligning strategies with business objectives.

Key Sessions and Speakers:

Build Core Competencies in Business Acumen and Strategic Thinking: Adeola Davis, Director of Learning & Development, Medical Affairs, Acadia Pharma, discussed strategies to enhance MSLs’ understanding of business operations, fostering a collaborative mindset aligned with corporate objectives.

Elevate MSL Performance with Well-Structured Collaborations with Medical Information Teams: Jason Bain, Medical Science Liaison, Exact Sciences, highlighted the importance of integrating Medical Information scientists into product teams to expedite responses to complex inquiries and improve partnership structures.

PANEL: Determine the Top Priorities for a Successful Insight Program: This panel focused on training MSLs to effectively gather and analyze insights, setting new standards for scientific exchange. Panelists included:

• Carl De Luca, Director, Field Medical Affairs – Oncology, Regeneron
• Ryan Van Puffelen, Senior Marketing Manager, KOL & Society Strategy, Johnson & Johnson

For those who could not attend, the summit is available on-demand, providing access to all sessions and discussions at your convenience.

• A hidden investor opportunity, Thumzup Media Corporation is starting to overturn the social media branding and marketing industry with an innovative approach to small business advertising
• The company expects to grow its advertiser network 10x by the end of the year, the first step toward getting 10% of America’s small businesses to advertise on the platform and directing 20% of their ad budgets to Thumzup
• This goal follows the 230% advertiser base growth seen in 2024, coupled with the company’s market expansion to South Florida and Greater Los Angeles

Thumzup (NASDAQ: TZUP), a Los Angeles-based company, is democratizing the $200 billion social media advertising industry with an increasingly popular platform designed to connect small-business advertisers directly with everyday social media users. The innovative approach has already attracted a growing list of customers, and the company has now listed on Nasdaq (https://ibn.fm/a9tlo).

Thumzup leverages a robust programmatic advertiser dashboard coupled with a consumer-facing App that allows individuals to get paid cash for posting about participating advertisers on major social media outlets. Given its integrations with Instagram, TikTok, and X (formerly Twitter), along with attribution tools and industry-leading analytics, Thumzup has managed to offer something unique in the market, a value proposition that its Founder and CEO, Robert Steele, believes will help the company reach its goal of a tenfold increase in advertisers over the next 12 months (https://ibn.fm/lQaZX).

In a recent letter to shareholders, Mr. Steele highlighted a 230% advertiser base growth for the 2024 calendar year. This meant that Thumzup crossed the 600 active advertisers mark and plans to grow the numbers substantially in 2025. The company also successfully listed on the Nasdaq and upsized its public offering to $8.2 million. These milestones were primarily driven by the company’s unique value proposition, product differentiation, and strong market positioning (https://ibn.fm/ZLQ7I).

Steele explained that Thumzup set out on an aggressive market expansion plan for 2024, having expanded to South Florida and Greater Los Angeles. The plan is now to scale nationwide with extended social media integrations, and its recently launched analytics tools based on customer feedback. In addition, following board approval in January 2025, the company approved a strategy to allocate up to 90% of liquid assets to Bitcoin (“BTC”). Currently, the company holds 19.106 BTC (https://ibn.fm/ZLQ7I).

Thumzup’s initial but consistent growth has made the company optimistic that it will realize and surpass its 2025 goal, with an approach that only Thumzup offers. For small-cap investors, this represents a still hidden opportunity to jump on an accelerating train that is redefining digital advertising.

“The future value proposition of Thumzup is immense. Just as hundreds of billions of dollars in value were created by democratizing ridesharing and hospitality, our platform can democratize the $200 billion social media advertising industry. To our knowledge, no one else is doing what we do,” noted Mr. Steele (https://ibn.fm/e2lny).

For company information, visit www.ThumzupMedia.com.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

The Pennsylvania Cannabis Convention (“PACC”) is gearing up to bring together growers, traders, brands, and enthusiasts to explore the legal cannabis sector in Pennsylvania on March 30, 2025. This event is a must-visit for those involved in the local cannabis industry, offering attendees in-depth insights into every aspect of the PA medical program. Registrations are open, and PA patients can attend the PACC for free.

For the March 30 event, PACC has partnered with NECANN, a renowned leader in hosting cannabis networking events. NECANN events are recognized as some of the premier cannabis gatherings on the East Coast, providing high ROI B2B opportunities. Each year, these events draw over 9,000 attendees, offering a platform for discovering new business and investment opportunities across the cannabis sector.

The event will take place at the David L. Lawrence Convention Center, covering nearly eight acres of space in downtown Pittsburgh. The venue offers an exceptional environment for events, meetings, and exhibitions, ensuring an unparalleled experience for all attendees.

With the expertise of NECANN, PACC is poised to create a vibrant and sustainable networking and business platform for local cannabis brands, growers, and retailers. The attendee list will include both startups and seasoned cannabis players, as well as key decision-makers within the industry. Exhibitors will have the opportunity to showcase their products and services while pitching their brands across various industry verticals. Licensed cultivators will present their innovative ideas and technologies, while investors can use the platform to discover new investment opportunities. Small businesses and newcomers will also have the chance to connect with industry veterans and forge lasting business relationships.

Ethos, the event’s presenting sponsor, includes a family of brands such as Natural Selections and Eleven, and will provide valuable insights on how enhanced cannabis products can help individuals improve their well-being.

To learn more, please visit https://ibn.fm/Uv0YK

The 9th Digital Strategy & Innovation for Medical Affairs Summit, held on February 26-27, 2025, in Philadelphia, brought together industry leaders to explore the transformative role of digital technologies in medical affairs. The event featured insightful discussions on artificial intelligence (“AI”), patient engagement, and innovative strategies to navigate the evolving technological landscape.

Key Sessions and Speakers:

Bridge Patient Care Gaps with AI-Driven, Omnichannel Engagement: This session delved into how AI-powered strategies are revolutionizing healthcare professional (“HCP”) engagement to address patient care gaps. Speakers included:

• Kyle Roderick, SVP of Medical Affairs at Doximity
• Amit Phull, Chief Physician Experience Officer at Doximity
• Div Khetia, VP, Head of Medical Affairs Channel Excellence at Pfizer

Utilize AI and Data Insights to Build Your Digitalization Roadmap: Nita Thingalaya, Lead Innovation and Evidence, Specialty Care, Sanofi, provided strategies for integrating AI processes by evaluating company capacity, logistics, and budget.

PANEL: Enhance Patient Autonomy by Using Advanced Technologies: This panel discussed how digital tools like wearable devices and electronic health records empower patients. Panelists included:

• Hiral Patel, System Director, Innovation Activation and Enablement, Endeavor Health
• Peter Covitz, Executive Director, Head Digital Innovation, Data Generation & Managed Access, Alexion Pharmaceuticals

Gain Efficiencies Through Fractional Medical Utilization: Mary Hames, CEO, BioLogic Pharma Solutions, explored the benefits of adopting fractional medical affairs teams for pre-commercial assets, highlighting how AI-powered tools can enhance productivity and strategic decision-making.

For those unable to attend, the summit is available on-demand.

Stay tuned for future events and continue to engage with the latest advancements in medical affairs.

• Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, just closed 10 new signings for its clubs in the 2024-2025 transfer window, 8 for the men’s teams and 2 for the women’s teams
• The company’s management believes that these new signings will bring fresh energy and expertise to their respective teams, positioning them for a successful second half of the season
• The signings follow an independent CFA’s valuation report projecting Brera’s revenues will triple in 2025

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, announced its new signings for its portfolio clubs ahead of the spring championship. According to its management, these additions reflect the company’s ongoing commitment to player development and expanding talent pathways, mainly from Africa and Eastern Europe (https://ibn.fm/7TLll).

The clubs that will benefit from these transfers include those in North Macedonia: Brera Strumica (mens), and Brera Tiverija (womens). The signees include Fodey Tavali (midfielder), Dragan Bilbia (defender), Fahd Nzengue (forward), Hadji Drame (right wing), Filip Mihailov (midfielder/attacker), Zoran Ivanovski (wing), Hristijan Jankuloski (defender) and Mihail Milevski (midfielder/defender), to cover the men’s team. Christine Nafula (forward) and Danche Karpuzzovska (midfielder/forward) will be the new additions to the women’s team.

The women’s team currently ranks first in their league, earning the title “winter champions.” Their two new additions, its management notes, will look to strengthen its position and defend its title this spring. In addition, the new signings, overall, will bring fresh energy and expertise into the respective teams, positioning them for a successful second half of the season (https://ibn.fm/7TLll).

These signings follow analyst projections that Brera’s revenues will triple in 2025. It was projected by an independent CFA report that for the 2025 financial year, the company will realize revenues of between $6.3 million and $9.8 million. While primarily influenced by the SS Juve Stabia acquisition of “The Second Team of Naples” in Italy’s Serie B, signings for the male and female teams in its portfolio also boost shareholder confidence and help drive the company’s earnings going forward.

“Brera Holdings made a strategic move with the Juve Stabia acquisition, and while challenges remain, the company is positioning itself for significant revenue growth,” noted Sascha P. Czerwenka, CFA, for 247MarketNews.com. “If operational improvements continue as expected, the stock could see a major re-rating, presenting a compelling opportunity for investors,”he added (https://ibn.fm/kf4Jr).

Brera remains committed to building competitive squads with diverse international talent, with its expansion into markers such as Asia and Africa being a testament to that.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA